Clinical Trials

    Showing 1 - 1 of 1 Kidney Cancers

    Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer (STRIKE)

    Status: Enrolling

    Investigator: Patrick Prath

    Study Coordinator: Syeda Sarwat

    Phone: 832.358.4365

    This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, such as pembr... Read more >